Novo Nordisk's Weekly Amycretin Delivers Up to 22% Weight Loss in Study, Stock...

Published on 24 Jan 2025 on Benzinga · via AOL

On Friday, Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with...

Read the rest of the article

Start tracking your investments with Statfolio

Drugmakers have poured small fortunes into the development of weight loss medicines in the past f...

Motley Fool · via Yahoo Finance 2 Feb 2025

(Bloomberg) -- Novo Nordisk A/S investors got a much-needed boost from last week’s trial results ...

Bloomberg · via Yahoo Finance 31 Jan 2025

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In...

Insider Monkey · via Yahoo Finance 30 Jan 2025

We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we a...

Insider Monkey · via Yahoo Finance 30 Jan 2025

We recently compiled a list of the Jim Cramer Discussed These 10 Stocks, AI Power Demand &...

Insider Monkey · via Yahoo Finance 29 Jan 2025

We recently compiled a list of the 12 Best Blue Chip Stocks to Buy Under $100. In this article, w...

Insider Monkey · via Yahoo Finance 29 Jan 2025

After analyzing data going back to 2016, one analyst thinks he has identified a seasonal pattern ...

The Wall Street Journal · via Yahoo Finance 29 Jan 2025

We recently published a list of Jim Cramer’s Latest Calls: 10 Stocks to Buy or Sell. In this...

Insider Monkey · via Yahoo Finance 27 Jan 2025

We recently published a list of 10 Best Stocks to Buy and Hold For 2025. In this article, we are...

Insider Monkey · via Yahoo Finance 25 Jan 2025

On Friday, Novo Nordisk A/S NVO released topline results from a phase 1b/2a trial with amycretin ...

Benzinga 24 Jan 2025